{"entity":{"id":"nct03592264","kind":"trial","name":"A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of AST-3424 run by OBI Pharma, Inc, terminated.","summary":"A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT03592264 by OBI Pharma, Inc, with 68 participants enrolled, started 2018-07-02. Conditions recorded: Solid Tumor and Pancreatic Adenocarcinoma. Interventions recorded: OBI-3424.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT03592264","url":"https://clinicaltrials.gov/study/NCT03592264"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["ast-3424"],"companies":["ascentawits-pharmaceuticals","obi-pharma","zhejiang-hisun"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03592264","phase":"1/2","setting":"A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors","sponsor":"OBI Pharma, Inc","enrolled":68,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03592264/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"ast-3424","kind":"drug","name":"AST-3424","route":"/drugs/ast-3424/"}],"company":[{"id":"ascentawits-pharmaceuticals","kind":"company","name":"Ascentawits Pharmaceuticals","route":"/companies/ascentawits-pharmaceuticals/"},{"id":"obi-pharma","kind":"company","name":"OBI Pharma","route":"/companies/obi-pharma/"},{"id":"zhejiang-hisun","kind":"company","name":"Zhejiang Hisun Pharmaceutical","route":"/companies/zhejiang-hisun/"}]}}